This application relates to a stent inserted in an eustachian tube for treatment of eustachian tube dysfunction. In one aspect, the stent includes a pressure controller which blocks the eustachian tube and is opened/closed according to a pressure difference between front and rear portions thereof to control a pressure in the eustachian tube. The stent may also include a eustachian tube expansion portion which is connected to the pressure controller and has a hollow portion passed therein to make a fluid move in back and forth directions of the eustachian tube, and is inserted in the eustachian tube to expand the eustachian tube by transforming a shape thereof in a radial direction of the eustachian tube.

A material for endobronchial occlusion capable of repairing or replacing tissue is disclosed. The material contains a protein (A), wherein the protein (A) contains at least one of a polypeptide chain (Y) or a polypeptide chain (Y′), a total number of the polypeptide chain (Y) and the polypeptide chain (Y′) in the protein (A) is 1 to 100, the polypeptide chain (Y) is a polypeptide chain consisting of 2 to 200 tandem repeats of at least one amino acid sequence (X) among an amino acid sequence VPGVG, an amino acid sequence GVGVP 4, GPP, GAP, and an amino acid sequence GAHGPAGPK, the polypeptide chain (Y′) is a polypeptide chain in which each of a total of 5% or less of amino acids in the polypeptide chain (Y) is replaced by at least one of a lysine residue or an arginine residue, with a total number of the lysine and arginine residues being 1 to 100.

A material for endobronchial occlusion capable of repairing or replacing tissue is disclosed. The material contains a protein (A), wherein the protein (A) contains at least one of a polypeptide chain (Y) or a polypeptide chain (Y′), a total number of the polypeptide chain (Y) and the polypeptide chain (Y′) in the protein (A) is 1 to 100, the polypeptide chain (Y) is a polypeptide chain consisting of 2 to 200 tandem repeats of at least one amino acid sequence (X) among an amino acid sequence VPGVG, an amino acid sequence GVGVP 4, GPP, GAP, and an amino acid sequence GAHGPAGPK, the polypeptide chain (Y′) is a polypeptide chain in which each of a total of 5% or less of amino acids in the polypeptide chain (Y) is replaced by at least one of a lysine residue or an arginine residue, with a total number of the lysine and arginine residues being 1 to 100.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

Porous implantable devices for housing one or more therapeutic agents are disclosed herein. The implantable devices include a porous outer wall defining an interia or void. The interior void houses a carrier material carrying a first therapeutic agent. The implantable devices are made by patterning at least a portion of a polymerizable substrate into a polymerized three-dimensional porous outer wall surrounding an interior void. This can be achieved by two-photon polymerization techniques. A first therapeutic agent is then added to the interior void, which is then sealed. Methods of treating diseases using the implantable devices are disclosed herein. The methods include implanting the implantable device at a target area and locally releasing a therapeutically effective dosage of a first therapeutic agent from the interior void. The implantable devices can also be used in methods of screening potentially therapeutic agents for desired biological responses.

A hybrid radiolucent screw having radiopaque components and radiolucent components, which collaboratively define a tip of the screw and a head of the screw. In this manner, distortion is minimized during fluoroscopy or radiography of the screw while visualization of the screw and surrounding area is enhanced.

A hybrid radiolucent screw having radiopaque components and radiolucent components, which collaboratively define a tip of the screw and a head of the screw. In this manner, distortion is minimized during fluoroscopy or radiography of the screw while visualization of the screw and surrounding area is enhanced.

An ophthalmological composition includes at least one viscoelastic polymer, wherein the composition comprises at least one thermoresponsive compound that in a predefined wavelength range undergoes a temperature-dependent discontinuous change in at least one physical property from a group color and transmittance. The disclosure further relates to such an ophthalmological composition wherein a temperature-dependent change in the at least one physical property is reversible and/or wherein the temperature-dependent change in the at least one physical property occurs within not more than 10 seconds after a predefined temperature threshold value has been exceeded.

A delivery guide wire (10,100) and a therapeutic device are disclosed. The therapeutic device includes the delivery guide wire (10, 100), a medical implant and a delivery catheter (20). The delivery guide wire (10, 100) includes a core shaft (110) and a driving member (120) disposed on the core shaft (110), and the driving member (120) defines thereon a depression. The medical implant is compressed by the delivery catheter (20) and disposed over the delivery guide wire (10,100) in such a manner that it is at least partially received in the depression. This results in an increased contact area between the medical implant and the delivery guide wire (10, 100), which facilitates movement of the medical implant in sync with the delivery guide wire (10, 100) and makes its delivery easier.